Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

[Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].

Takeda K, Shigematsu T, Shirai M, Yamagiwa K, Amamori K, Sunda K, Yamanda T.

Gan To Kagaku Ryoho. 2012 Dec;39 Suppl 1:74-6. Japanese.

PMID:
23268906
2.

Management of hand-foot syndrome induced by capecitabine.

Gressett SM, Stanford BL, Hardwicke F.

J Oncol Pharm Pract. 2006 Sep;12(3):131-41. Review.

PMID:
17022868
3.

Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

Lassere Y, Hoff P.

Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. Review.

PMID:
15341880
4.

Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.

Hoesly FJ, Baker SG, Gunawardane ND, Cotliar JA.

Arch Dermatol. 2011 Dec;147(12):1418-23. doi: 10.1001/archdermatol.2011.320. Review.

PMID:
22184763
5.

Capecitabine and hand-foot syndrome.

Saif MW.

Expert Opin Drug Saf. 2011 Mar;10(2):159-69. doi: 10.1517/14740338.2011.546342. Epub 2010 Dec 22. Review.

PMID:
21174613
6.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
7.

Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).

Marsé H, Van Cutsem E, Grothey A, Valverde S.

Eur J Oncol Nurs. 2004;8 Suppl 1:S16-30. Review.

PMID:
15341879
8.
9.
10.

Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.

Scheithauer W, Blum J.

Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173; discussion 1173-6, 1181-4. Review.

11.

Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.

Wang Y, Yang H, Wei JF, Meng L.

Curr Med Res Opin. 2012 Dec;28(12):1911-9. doi: 10.1185/03007995.2012.748655. Epub 2012 Nov 27. Review.

PMID:
23145857
12.

Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.

Aprile G, Mazzer M, Moroso S, Puglisi F.

Anticancer Drugs. 2009 Apr;20(4):217-29. doi: 10.1097/CAD.0b013e3283293fd4. Review.

PMID:
19247178
13.

Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.

Narasimhan P, Narasimhan S, Hitti IF, Rachita M.

Cutis. 2004 Feb;73(2):101-6. Review.

PMID:
15027515
14.

[Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine].

Wang Y, Xu RR.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Feb;27(2):182-4. Review. Chinese.

PMID:
17343012
15.

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.

Leonard R, Hennessy BT, Blum JL, O'Shaughnessy J.

Clin Breast Cancer. 2011 Dec;11(6):349-56. doi: 10.1016/j.clbc.2011.06.005. Review.

PMID:
21856245
16.

[Capecitabine].

Yamaguchi K, Shimamura T, Tada M.

Gan To Kagaku Ryoho. 2006 Jul;33(7):891-5. Review. Japanese.

PMID:
16835474
17.

Unilateral hand-foot syndrome: does it take sides? Case report and literature review.

Almeida da Cruz L, Hoff PM, Ferrari CL, Riechelmann RS.

Clin Colorectal Cancer. 2012 Mar;11(1):82-4. doi: 10.1016/j.clcc.2011.05.004. Epub 2011 Jul 20. Review. No abstract available.

PMID:
21764392
18.
19.

Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.

Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC.

J Clin Pharm Ther. 2012 Jun;37(3):266-75. doi: 10.1111/j.1365-2710.2011.01289.x. Epub 2011 Sep 26. Review.

PMID:
21950464
20.

New options for outpatient chemotherapy--the role of oral fluoropyrimidines.

Cunningham D, Coleman R.

Cancer Treat Rev. 2001 Aug;27(4):211-20. Review.

PMID:
11545541

Supplemental Content

Support Center